Current Report Filing (8-k)

Date : 12/12/2018 @ 4:30PM
Source : Edgar (US Regulatory)
Stock : Vitro Diagnostics, Inc. (PN) (VODG)
Quote : 0.229  0.0 (0.00%) @ 2:30PM

Current Report Filing (8-k)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):      December 6, 2018

 

VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

 

       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

 

4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)

 

Registrant's telephone number, including area code:    (303) 999-2130

 

______________________________________________________

(Former name or former address, if changed since last report)

 

 

___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [ X ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.              [     ]


 

ITEM 4.01 CHANGES IN REGISTRANT’S INDEPENDENT REGISTERED PUBLIC  

ACCOUNTANT

 

Effective December 6, 2018, the Company’s independent registered public accountants Schumacher & Associates, Inc. (“Schumacher”) informed the Company that they resigned as the Company’s independent registered public accountants. In the period from Schumacher & Associates, Inc.’s appointment in 2007 until December 6, 2018 (the date of resignation), there were no disagreements with Schumacher & Associates, Inc. on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of Schumacher & Associates, Inc., would have caused Schumacher & Associates, Inc. to make reference to the matter in its report on the Company’s financial statements; and there were no reportable events as defined in Item 304(a) (1) of Regulation S-K.  Schumacher & Associates, Inc., issued audit reports on our financial statements as of and for the years ended October 31, 2006 through 2015 which reports each included an explanatory paragraph concerning the Company’s ability to continue as a going concern.

 

As of the date of this Report, the Company has not appointed a successor independent registered public accountant.

 

The Company has provided Schumacher & Associates, Inc. with a copy of the above disclosures. Attached as Exhibit 16 is a copy of Schumacher & Associates, Inc.’s letter, dated December 7, 2018, stating its agreement with such statements.

  Item 9.01 Financial Statements and Exhibits

 

(a)

Financial statements of businesses acquired.

 

Not applicable

 

(b)

Pro forma financial information.

 

Not applicable

 

(c)        Shell company transactions.  

 

Not applicable

 

(d)

Exhibits

 

 

Item

Title

 

 

 

 

16.0

Pursuant to Item 304(a)(1) of Regulation S-K, the Registrant herewith files the letter of Schumacher & Associates, Inc., former accountants to the Company.


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

 

Dated:   December 7, 2018

 

__ _/s/ James R. Musick__ ____
James R. Musick, President and CEO

 

 

 

 

 

Vitro Diagnostics, Inc. (PN) (USOTC:VODG)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Vitro Diagnostics, Inc. (PN) Charts.

Vitro Diagnostics, Inc. (PN) (USOTC:VODG)
Intraday Stock Chart

Today : Monday 21 October 2019

Click Here for more Vitro Diagnostics, Inc. (PN) Charts.

Latest VODG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.